
	Where results make sense

Topic: HAART

Related Topics

Antiretroviral drug

Enfuvirtide

Protease inhibitor (pharmacology)

AZT

HIV vaccine

Hydroxyurea

AIDS

Treatment Action Campaign

HIV test

HIV

AIDS reappraisal

AIDS in Africa

OPV AIDS hypothesis

Grantha

Fetal hemoglobin

In the News (Fri 25 Jul 08)

Gordon Brown

Derby County

Mike Huckabee

Lute Olson

Pearl Harbor

Sonia Gandhi

Ricky Hatton

Narendra Modi

Jesus Christ

Rudy Giuliani

	Increasing Trend to Stop HAART in MACS
		The increasing trend of discontinuation of HAART in this cohort was consistent with a report from the Women's Interagency HIV Study (WIHS).
		Overall, 32.6% of the group who interrupted HAART reported that the interruption was prescribed by their physician.
		Whereas the continuous HAART users had an annual increase of 10.6% (95% CI: 9.2, 12.0) on average by Vi+2, the discontinuers overall had an annualized loss of 1.3% of their Vi CD4 cell count at Vi+2, representing a significant (P = 0.02) difference in the change of CD4 cell count.
	www.natap.org /2005/HIV/040405_02.htm (1875 words)

	Research Initiative/Treatment Action! (Site not responding. Last check: 2007-10-12)
		In this regard, it is important to keep in mind that unlike the case with KS, chemotherapy for ARL is administered with curative intent and that a number of studies have suggested that failure to achieve a durable complete response with the first regimen portends a poor overall prognosis.
		HAART would not be expected to prevent the lympholytic effects of chemotherapy, and if it did, would raise concern that it was also protecting against lympholysis of the malignant cells.
		HAART should be used either as the only component of anti-tumor therapy or in combination with additional specific anti-KS therapy depending on the extent and aggressiveness of the KS.
	www.centerforaids.org /rita/0903/chemo.htm (3773 words)

	AEGiS-RITA!: SIMPLY STATED: Surviving with HIV in the HAART era: emerging challenges - September 2000
		Perhaps most ironic for HIV-infected people living in the HAART era is the risk for disorders like insulin resistance and elevated cholesterol and triglyceride levels, which commonly threaten the general population.
		Since widespread use of HAART is scarcely 5 years old, another 5 years may be required to observe any effects on the survival of these patients.
		HAART results in an improved chemotherapy response and overall survival in patients with AIDS-related lymphoma.
	www.aegis.com /pubs/rita/2000/RI000904.html (1572 words)

	When To Begin HAART: new study & 2 different opinions
		Finally, HAART regimens in current use (e.g., those that include efavirenz- or ritonavir-boosted protease inhibitors) may be more potent and/or have a better pharmacokinetic profile (allowing for less-frequent dosing and perhaps better adherence) than were the HAART regimens used during the study period.
		The date for initiation of HAART or switching from any other antiretroviral therapy to HAART (hereafter, both are considered to be the initiation of HAART) was estimated to be the midpoint between the visit at which receipt of HAART was first reported and the previous visit.
		CD4 cell counts at initiation of HAART were based on the average of the measurements from the last 2 visits before the first visit at which receipt of HAART was reported.
	www.natap.org /2004/HIV/090804_09.htm (3875 words)

	HIV Report March 2003: Taking HAART to Heart: Antiretroviral Toxicities (Site not responding. Last check: 2007-10-12)
		By Gregory M. Lucas, M.D. The benefits of HAART are abundantly clear in wealthy countries, and the focus of many researchers, governmental agencies and private benefactors has appropriately shifted to bringing this therapy to the developing world.
		As experience with HAART accrues, defining the mechanisms of antiretroviral-related toxicity, quantifying risk, and devising strategies to minimize toxicity have become major areas of research, and were well represented at this year's CROI.
		HAART has been associated with a disadvantageous cardiovascular risk profile, including hyperlipidemia, truncal obesity, insulin resistance and diabetes.
	hopkins-aids.edu /publications/report/mar03_5.html (1841 words)

	SF AIDS Fdn: BETA Spring 2000 -- HIV Persists Despite HAART
		If all HAART left was a latent pool of HIV-infected cells that occasionally became active and spewed out new virions, then immune stimulants might have a measurable effect when combined with a suppressive anti-HIV regimen.
		Discontinuation of HAART after a course of therapeutic vaccination with ALVAC 1452 and rgp160 may be associated with delayed viral rebound kinetics.
		The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.
	www.sfaf.org /treatment/beta/b43/b43persists.html (5265 words)

	HAART Alone Is Not Enough to Produce Tumor Regression in Most Cases of Moderate-Advanced Kaposi's Sarcoma
		For this study, twenty-eight HIV patients either naive or failing highly active antiretroviral therapy (HAART) with moderate-advanced Kaposi's sarcoma (KS) were randomly chosen to initiate a new HAART regimen plus pegylated liposomal doxorubicin (PLD) or the new HAART regimen alone.
		The results indicate that HAART alone is not enough to produce tumour regression in most cases of moderate-advanced KS.
		In this context, it is more probable that HAART was not able to control the natural progression of the disease than that there was an immune-mediated KS deterioration.
	www.hivandhepatitis.com /recent/haart/081104_b.html (1132 words)

	Clinical Trial: Intermittent vs. Continuous HAART to Treat Chronic HIV Infection
		HAART is a multi-drug regimen that is very effective in suppressing HIV and perhaps slowing or halting progression to AIDS.
		HIV-infected people age 18 or older who are receiving HAART and have a viral load of less than 50 copies/ml and a CD4+ T cell count of at least 175 cells/mm3 may be eligible for this study.
		These recent observations may argue for a different approach to HAART with the goals of : 1) durable suppression of virus replication, without an attempt at eradication, 2) minimization of toxicity and side effects and improvement in patient life-style, and 3) a reduction in cost.
	clinicaltrials.gov /ct/show/NCT00025909?order=30 (1268 words)

	High Survival Odds Seen When HAART Is Used Early and Continuously (Site not responding. Last check: 2007-10-12)
		If HAART was delayed or not used continuously, these CD4+ cell thresholds had to be higher to achieve the same survival odds.
		When HAART was delayed for 1 year from the time of treatment eligibility, a count of 110 cells/microliter was needed for this survival probability.
		Therefore, deferring HAART in such patients due to toxicity or adherence concerns may be acceptable, they add.
	www.hivandhepatitis.com /recent/haart/110703g.html (395 words)

	p990928a - Highly Active AntiRetroviral Therapy (HAART)
		Our data suggest that HAART may be continued also in the absence of a significant HIV RNA decrease if alternative drugs are not available.
		Most HAART regimens include drugs from at least two of the three classes of antiretroviral therapy (nucleoside analog reverse transcriptase (RT) inhibitors, non-nucleoside analog RT inhibitors, and protease inhibitors).
		In deciding when to initiate antiretroviral therapy, physicians and their patients must balance the virological and immunological benefits of early treatment with the costs of drug therapy, the risk of drug side effects, and the risk of drug resistance if adherence is suboptimal.
	www.emory.edu /WHSCL/grady/amreport/litsrch99/p990928a.html (520 words)

	Antiretroviral drug - Wikipedia, the free encyclopedia
		Various combinations of three or four drugs are known as HAART or Highly Active Anti Retroviral Therapy.
		However, there remain a range of views on this subject and ultimately the decision to commence or not to commence treatment rests with the patient and their doctor.
		In the event that a person's HIV infection becomes resistant to standard HAART there are limited options.
	en.wikipedia.org /wiki/Antiretroviral_drug (3708 words)

	HIV & AIDS - Concerns about HAART (Highly Active Anti-Retroviral Therapy)
		HAART is the therapy, composed of multiple anti-HIV drugs, that is prescribed to many HIV-positive people, even before they develop symptoms of AIDS (and without considering that many will never develop these symptoms).
		The HAART regimens included 3-5 anti-retroviral agents at least one of which was a protease inhibitor...After 18 months, 14 percent of the population remained asymptomatic, 10 percent of which had an undetectable viral load.
		She had been taking indinavir, stavudine and lamivudine for 19 months...A male aged 42 years with AIDS presented with preogressive weight loss, tremor,, and tachycardia....The patient had been on indinavir, stavudine, and lamivudine for 16 months...A man aged 36 years with AIDS was started on ritonavir, stavudine and lamivudine in April, 1996.
	www.virusmyth.net /aids/data/dchaart.htm (9597 words)

	AEGiS-BETA: Women, Access, and Adherence to HAART: A Vital Connection - Spring, 2000
		Once an individual has access to HAART, it is also critically important that she or he adhere closely to the regimen in order to maximally benefit.
		Overall, optimizing adherence to HAART has two key components: 1) choosing a regimen that is as simple as possible while incorporating the needed potency, and 2) providing intensive, individualized education and logistical support to optimize the likelihood of maximal adherence.
		As mentioned earlier, when individuals taking or initiating HAART have active mental health or substance abuse problems, it will be more difficult for them to adhere to their drug regimen than for others without such issues.
	www.aegis.com /pubs/beta/2000/be000408.html (3164 words)

	Highly active antiretrovival therapy (HAART) and hospice
		In one cohort study, over a third of patients who discontinued HAART experienced symptoms related to discontinuation.(1) However, the onset of symptoms is often 1-2 months after discontinuation of HAART, and the majority of patients do not experience symptoms, so this potential benefit should be balanced by considerations of treatment burden and life expectancy.
		HAART reduces the incidence of opportunistic infections that impact the quality of life of patients with AIDS.
		Since the role of HAART near the end of life is uncertain, hospice agencies may decide to decline payment.
	www.mywhatever.com /cifwriter/library/eperc/fastfact/ff102.html (837 words)

	Adherence: The Key to Successful HAART (Site not responding. Last check: 2007-10-12)
		While there are, of course, many reasons for HAART not being successful, including medication intolerance, prior ineffective antiretroviral therapy and infection with a drug-resistant strain of HIV, nonadherence and nonpersistence with antiretroviral therapy is far and away the major reason most patients fail to get any benefit from and develop resistance to HAART.
		From the patient's perspective, HAART has been shown to reduce the risk of virologic failure of HAART, to extend the patient's lifespan and reduce the risk of progression to AIDS, and to reduce the risk of the development of resistance.
		Thus, decreasing viral burden in HIV-infected patients using HAART is an important component of decreasing the spread of HIV, because high-risk behavior appears to be rising and accidents, such as condoms breaking, are inevitable.
	www.hivandhepatitis.com /recent/adh/111703.html (4702 words)

	Concerns about HAART (Highly Active Anti-Retroviral Therapy)
		This is particularly true with HAART both due to its toxicity and the fact that treatment may be quite coercive, particularly towards parents of HIV-positive children.
		Many HAART studies did not state, however, whether patients with undetectable HIV-1 RNA at study conclusion and who switched study drug during the trial were classified as virological failures.
		The HAART regimens included 3-5 anti-retroviral agents at least one of which was a protease inhibitor...After 18 months, 14% of the population remained asymptomatic, 10% of which had an undetectable viral load.
	www.aras.ab.ca /haart.html (13524 words)

	The Body: Hepatitis C Found to Diminish Response to HAART
		But the size of this increase may be affected by several factors, including the ability to take medications as prescribed and directed (adherence).
		The fact that the response to HAART was worse in co-infected people raises questions about the timing for initiating HIV therapy in this population.
		Perhaps HAART would be more effective in HCV co-infected people if taken earlier in the course of HIV disease, when their CD4+ counts are higher?
	www.thebody.com /catie/hcv_haart.html?m8 (639 words)

	Changes In Clinical Progression To AIDS In Patients On HAART Therapy
		A new study following 12,574 individuals over the course of three years of HAART and tracking the incidence and type of these AIDS-defining events appears in the February 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
		Treatment with HAART results in a dramatic reduction in the incidence of AIDS and death in individuals infected with HIV, according to background information in the article.
		Many of the patients included in early studies on HAART had been exposed to prior treatment with one or more of the HAART medications (usually nucleoside reverse transcriptase inhibitors [NRTIs]) before beginning HAART.
	www.sciencedaily.com /releases/2005/03/050308093606.htm (701 words)

	Biopeer: Combating HIV through rAAV (Site not responding. Last check: 2007-10-12)
		Since a classical vaccine against HIV-1 is hard to design or even define, and since current HAART (highly-active-anti-retroviral-therapy) and even Mega-HAART regimens are unable to clear an HIV-1 infection, a combined strategy has to be adopted, in order to achieve HIV-1 eradication.
		as effective as HAART), provided that it is preceded by a multivalent-polivalent-therapeutic-vaccine (MPTV-x) containing killed HIV-1 (or particular parts of HIV-1) bearing on its genome (biochemical structure) the resistance-mutations-pattern(RMP) of AZT.
		Current HAART and Mega-HAART-x regimens make STEP1 possible for prolonged periods of time.
	www.biopeer.com /biopeer/2005/05/strongcombating.html (3041 words)

	Starting highly active antiretroviral therapy: why, when and response to HAART -- Mocroft and Lundgren 54 (1): 10 -- ...
		CD4 cell count before HAART (Table 1), with conflicting results.
		HAART reported from clinical trials tends to be considerably
		Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort.
	jac.oxfordjournals.org /cgi/content/full/54/1/10 (2228 words)

	JAMA -- Abstract: Impact of HIV Infection and HAART on Serum Lipids in Men, June 11, 2003, Riddler et al. 289 (22): 2978
		JAMA -- Abstract: Impact of HIV Infection and HAART on Serum Lipids in Men, June 11, 2003, Riddler et al.
		Impact of HIV Infection and HAART on Serum Lipids in Men
		Subsequent HAART initiation is associated with increases in
	jama.ama-assn.org /cgi/content/abstract/289/22/2978 (449 words)

	Clinical Trial: Garlic in Hyperlipidemia Caused by HAART
		The purpose of this study is to test the effectiveness and tolerability of garlic pills in lowering cholesterol and triglycerides in hyperlipidemic HIV-infected individuals who are being treated with highly active antiretroviral therapy (HAART).
		Second, there is a growing body of studies that indicate that garlic exhibits lipid and glucose lowering as well as hepato-protective activities.
		Third, several of the pharmacological activities of garlic and their reported clinical benefits in other conditions, especially in hyperlipidemia, may be relevant in the management of highly active antiretroviral therapy (HAART) in HIV-infected subjects.
	clinicaltrials.gov /show/NCT00029250 (456 words)

	Incidence of Oral Lesions in HIV-1-infected Women: Reduction with HAART -- Greenspan et al. 83 (2): 145 -- Journal of ...
		Incidence of Oral Lesions in HIV-1-infected Women: Reduction with HAART -- Greenspan et al.
		Incidence of Oral Lesions in HIV-1-infected Women: Reduction with HAART
		Few studies assess the effectiveness of HAART on reducing the
	jdr.iadrjournals.org /cgi/content/abstract/83/2/145 (215 words)

	Regulation of Plasma PAI-1 Concentrations in HAART-Associated Lipodystrophy During Rosiglitazone Therapy -- ...
		compromise the improved prognosis conferred by HAART by increasing
		Several mouse models of LD have documented that neither subcutaneous
		LD+ indicates HIV+ patients with HAART-associated lipodystrophy; LD-, HIV+ patients using HAART but without LD; HIV-, HIV- normal subjects; and ß2 MG, ß2 microglobulin.
	atvb.ahajournals.org /cgi/content/full/23/4/688 (3502 words)

Try your search on: Qwika (all wikis)